Related Experiment Video
Updated: May 20, 2025

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells
Published on: June 2, 2022
Expression of Human β3GalT5-1 in Insect Cells as Active Glycoforms for the Efficient Synthesis of Cancer-Associated
Chih-Chuan Kung1, Jennifer M Lo1, Kuo-Shiang Liao1
1Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan.
Abstract:
The globo-series glycosphingolipids (GSLs) are unique glycolipids exclusively expressed on the cell surface of various types of cancer and have been used as targets for the development of cancer vaccines and therapeutics. A practical enzymatic method has been developed for the synthesis of globo-series glycans, where the conversion of Gb4 to Gb5 (SSEA-3) glycan based on the microbial galactosyltransferase LgtD is relatively inefficient compared to other steps. To improve the efficiency, we explored the two human galactosyltransferase (β3GalT5) isozymes in cancer cells for this reaction and found that isozyme 1 (β3GalT5-1) is more active than isozyme 2 (β3GalT5-2). We then identified a common soluble domain of the two β3GalT5 isozymes as a candidate and evaluated the activity and substrate specificity of the glycosylated and nonglycosylated glycoforms. The glycoforms expressed in Sf9 cells were selected, and a site-specific alanine scan was performed to identify S66A β3GalT5 variant with 10-fold more efficiency than LgtD for the synthesis of globo-series glycans. The X-ray structure of β3GalT5-1 was determined for molecular modeling, and the result together with kinetic data were used to rationalize the improvement in catalysis.
Insights
Researchers engineered a human enzyme, beta3GalT5-1, to efficiently synthesize globo-series glycans, crucial targets in cancer therapy. This engineered enzyme is 10-fold more effective than previous methods for producing these cancer-targeting molecules.
Area of Science:
- Glycobiology
- Enzymology
- Cancer Therapeutics
Background:
- Globo-series glycosphingolipids (GSLs) are cell surface markers found on various cancers, making them targets for cancer vaccines and therapeutics.
- Current enzymatic synthesis of globo-series glycans, particularly the conversion of Gb4 to Gb5 (SSEA-3), using microbial galactosyltransferase LgtD, is inefficient.
Purpose of the Study:
- To enhance the efficiency of globo-series glycan synthesis by exploring human galactosyltransferases.
- To identify and engineer a highly efficient human enzyme for the synthesis of globo-series glycans for cancer therapeutic development.
Main Methods:
- Screened human beta-1,3-galactosyltransferase (β3GalT5) isozymes (1 and 2) for improved Gb4 to Gb5 conversion efficiency.
- Evaluated activity and substrate specificity of different glycoforms of a common soluble domain of β3GalT5.
- Utilized site-specific alanine scanning to identify a highly active variant (S66A β3GalT5).
- Determined the X-ray structure of β3GalT5-1 for molecular modeling and mechanistic insights.
Main Results:
- Human β3GalT5 isozyme 1 (β3GalT5-1) demonstrated higher activity than isozyme 2 (β3GalT5-2) in the synthesis of globo-series glycans.
- A S66A variant of β3GalT5-1 was identified with a 10-fold increase in efficiency compared to the microbial LgtD.
- Structural and kinetic analyses provided rationale for the enhanced catalytic efficiency of the engineered enzyme.
Conclusions:
- Engineered human β3GalT5-1 (S66A variant) offers a significantly more efficient enzymatic method for synthesizing globo-series glycans.
- This improved synthesis provides a valuable tool for the development of novel cancer vaccines and therapeutics targeting GSLs.
More Related Videos
11:42High Yield Expression of Recombinant Human Proteins with the Transient Transfection of HEK293 Cells in Suspension
Published on: December 28, 2015
08:58Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
Published on: July 5, 2018
Related Concept Videos
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Reporter Genes
Protein Glycosylation
Glycosylation occurs in...